Pfizer Inc. (PFE) Stock Analysis

Verdict: HOLD

Non-COVID portfolio momentum and high 5.38% yield support recovery, but looming 2026-2028 patent cliffs and debt keep valuation capped.

Investment score: 61/100

Analysis as of

Is Pfizer Inc. stock worth reviewing? The TradeMates thesis

The TradeMates model sees Pfizer Inc. (PFE) as a HOLD at $30.64, balancing operational execution in its non-COVID base and a 5.38% dividend yield against patent cliff headwinds and elevated leverage.

7-factor investment score

Pfizer Inc. opportunities and risks

What speaks for PFE

What speaks against PFE

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
PFE43.4x2.7x21.2x77.9%6.4%6.7%
LLY45.7x15.4x30.7x83.6%31.9%1.5%
JNJ41.0x6.6x22.0x68.8%16.2%3.2%
MRK151.4x5.4x31.7x77.0%3.6%4.4%
BMY13.9x2.6x10.8x69.2%18.5%7.2%
RPRX27.6x11.7x22.0x89.4%32.1%10.0%
Peer median41.0x6.6x22.0x77.0%18.5%4.4%

Frequently asked questions about Pfizer Inc. (PFE)

Is PFE stock a good investment?

The TradeMates model rates Pfizer Inc. as HOLD with an investment score of 61/100. The TradeMates model sees Pfizer Inc. (PFE) as a HOLD at $30.64, balancing operational execution in its non-COVID base and a 5.38% dividend yield against patent cliff headwinds and elevated leverage. This is algorithmic model output, not personal investment advice.

Is PFE stock a buy?

The TradeMates model verdict for PFE is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.